Telmisartan in preventing epirubicin-induced myocardial disorders in patients with cancer who are receiving epirubicin

Trial Profile

Telmisartan in preventing epirubicin-induced myocardial disorders in patients with cancer who are receiving epirubicin

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2011

At a glance

  • Drugs Telmisartan (Primary)
  • Indications Heart failure; Myocardial disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Oct 2010 Interim results presented at the 35th Congress of the European Society for Medical Oncology (ESMO).
    • 04 Jun 2010 Interim results presented at the4 6th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top